Stockscreener 앱 받기
20.70
2.95%
-0.5157
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Wolfe Research initiates Alto Neuroscience stock with outperform rating - Investing.com India
Alto Neuroscience Analyst Ratings and Price Targets | NYSE:ANRO - Benzinga
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
BofA Securities Adjusts Price Target on Alto Neuroscience to $33 From $35 - marketscreener.com
Wolfe Research initiates Alto Neuroscience stock with outperform rating By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained - TipRanks
Alto Neuroscience Is Maintained at Outperform by Baird - Moomoo
Alto Neuroscience Price Target Cut to $36.00/Share From $38.00 by Baird - Moomoo
Alto Neuroscience (ANRO) CEO gifts 400,000 shares to family trust - Stock Titan
Alto Neuroscience (ANRO) Vestal Point reports 6.5% ownership - Stock Titan
Point72 affiliates, Steven A. Cohen hold 3.7% of Alto Neuroscience (ANRO) - Stock Titan
[SCHEDULE 13G/A] Alto Neuroscience, Inc. Amended Passive Investment Disclosure - Stock Titan
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT) - The Globe and Mail
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Mental health scientist wins Columbia Transformational Research Award - Stock Titan
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Business Wire
Sirenia, Alex Silverstein disclose 7.9% stake in Alto Neuroscience (ANRO) - Stock Titan
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Alto Neuroscience (NASDAQ: ANRO) director receives 10,958 stock option grant - Stock Titan
Alto Neuroscience (ANRO) director gets 10,958 options at $24.63 strike - Stock Titan
Alto Neuroscience (ANRO) director receives 10,958-share stock option grant - Stock Titan
Alto Neuroscience (ANRO) director awarded 10,958 stock options as compensation - Stock Titan
York Gwill receives 10,958 Alto Neuroscience (ANRO) stock options grant - Stock Titan
A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $24 to $28 - Moomoo
ANRO: ALTO-207 demonstrates robust efficacy in TRD, with late-stage trials and major catalysts ahead - TradingView
Alto Neuroscience: Runway To Fund Planned Operations Through 2029 >ANRO - Moomoo
Alto Neuroscience Shareholders Shape Governance and Equity Plans - TipRanks
Alto Neuroscience (ANRO) OKs ESPP amendment but rejects equity plan change - Stock Titan
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $35.52, Implies 44% Upside - TradingView
Alto Neuroscience, Inc. Reports Q1 2026 Financial Results and Provides Business Update - Minichart
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Alto Neuroscience Announces Strong Q1 2026 Results, Launches Pivotal Phase 2b Trial for ALTO-207 in Treatment-Resistant Depression and Secures $120M Financing 1 - Minichart
Alto Neuroscience Releases Q1 2026 Financial Results - AlphaStreet
Alto Neuroscience : Corporate Presentation - marketscreener.com
Alto Neuroscience Q1 Loss Widens - Moomoo
Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss - marketscreener.com
[10-Q] Alto Neuroscience, Inc. Quarterly Earnings Report - Stock Titan
Alto Neuroscience reports Q1 2026 net loss of $26.2M, cash of $264.2M after $120M PIPE - TradingView
Alto Neuroscience (NYSE: ANRO) boosts cash with $120M PIPE and funds runway to 2029 - Stock Titan
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights - standard-journal.com
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Alto Neuroscience Announces Participation in Upcoming Investor ConferencesMay 11, 2026 - BioSpace
Alto Neuroscience (NYSE:ANRO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Alto Says Investors Use Hindsight In Suit Over Drug Trial - Law360
Alto Neuroscience (ANRO) Price Target Increased by 81.11% to 19.09 - MSN
BofA Securities initiated coverage on Alto Neuroscience with a new price target - Quantisnow
BofA Securities Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $35 - Moomoo
BofA initiates Alto Neuroscience stock coverage with buy rating By Investing.com - Investing.com India
BofA initiates Alto Neuroscience stock coverage with buy rating - Investing.com
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting - BioSpace
Alto Neuroscience reports positive phase 2a depression trial By Investing.com - Investing.com South Africa
2.25%
0.46%
자본화:
|
볼륨(24시간):